Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics

Recent studies have reported an increased risk of second primary malignancies (SPM) following multiple myeloma (MM) diagnosis associated with novel anti-myeloma treatments. We evaluated the risk of SPM among 36 491 MM cases reported to the Surveillance, Epidemiology, and End Results program (SEER) b...

Descripción completa

Detalles Bibliográficos
Autores principales: Razavi, P, Rand, K A, Cozen, W, Chanan-Khan, A, Usmani, S, Ailawadhi, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698537/
https://www.ncbi.nlm.nih.gov/pubmed/23811785
http://dx.doi.org/10.1038/bcj.2013.19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698537/
https://www.ncbi.nlm.nih.gov/pubmed/23811785
http://dx.doi.org/10.1038/bcj.2013.19

Ejemplares similares